Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease

Variations in time to benefit among clinical trials of cholesterol-lowering drugs

(2018) Philip J. Barter et al.   Journal of Clinical Lipidology

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

(2017) A. Michael Lincoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin TherapyCLINICAL PERSPECTIVE

(2016) Ian Ford et al.   CIRCULATION

Interpretation of the evidence for the efficacy and safety of statin therapy

(2016) Rory Collins et al.   LANCET

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials

(2015)   LANCET

Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

(2014) Antonio M. Gotto et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

(2013) Antonio M. Gotto et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial

(2013) Heart Protection Study Collaborative Group   LANCET

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib

(2012) Michael Davidson et al.   JOURNAL OF LIPID RESEARCH

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION